Status: Recruiting
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic stem cell transplantation in a cohort of pediatric and young adult patients with chemorefractory or minimal residual disease (MRD) positive acute leukemia.
Participants needed: 15
Trial details
Phase: Phase 2Age: 1-25Biological sex: AllType: InterventionalSponsor: Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyUpdated: Dec 1, 2025Locations: 1
Eligibility criteria
Patient (age from 14 to 25 years) and/or patient's legal representative (age fro... [+12]
Inability to provide or withdrawal of written informed consent. [+6]